Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Paschka

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Annals of the New York Academy of Sciences|June 12, 2003
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemiaTim H Brummendorf, Inci Ersoz, Ulrike Hartmann, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Haematologica|July 4, 2007
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMartin C Müller, Guiseppe Saglio, Feng Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study groupVerena I Gaidzik, Lars Bullinger, Richard F Schlenk, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Annals of the New York Academy of Sciences|June 12, 2003
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemiaTim H Brummendorf, Inci Ersoz, Ulrike Hartmann, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Haematologica|July 4, 2007
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMartin C Müller, Guiseppe Saglio, Feng Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyChristian Langer, Guido Marcucci, Kelsi B Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study groupVerena I Gaidzik, Lars Bullinger, Richard F Schlenk, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Pageof 8